Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug719 | COPAN swabbing and blood sample collection Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| D018352 | Coronavirus Infections NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The novel coronavirus disease (COVID-19) is posing a serious challenge to the health-care systems worldwide, with an enormous impact on health conditions and loss of lives. More than 30 millions of recoveries worldwide were registered at the end of October 2020 with more than 1 million of deaths. As the disease continues to spread, strategies aimed to reduce hospitalization time in sub intensive unit care, thus reducing pressure on health system, but also to reduce some of the pathological features of COVID-19 such as inflammation and the "cytokines storm". The ketogenic diet is a high fat, low carbohydrate, adequate-protein diet that promotes a physiological ketosis (due to an increase of liver ketone bodies production). High fat, low carbohydrate diets have been shown to reduce duration of ventilator support and partial pressure carbon dioxide in patients with acute respiratory failure. Moreover, the physiological increase in plasma levels of ketone bodies exerts important anti-inflammatory and immunomodulating effects, which may reveal as precious tools to reduce potential adverse outcomes of COVID-19 disease. The hypothesis of this study is that the administration of a ketogenic diet will improve gas exchange, reduce inflammation, and the duration of hospitalization. The plan is to enrol 28 patients with diagnosis of COVID-19 hospitalized but not in ICU with SPO2 higher than 88%.
Description: change in IL-6 levels. IL-6 is an inflammatory cytokine. Units: in pg/mL
Measure: inflammation panel: interleukine 6 (IL-6) Time: Daily until patient's hospital discharge, up to 30 daysDescription: change in TNFα levels. TNFα is an inflammatory cytokine Units: pg/mL
Measure: inflammation panel: tumor necrosis factor alfa (TNFα) Time: Daily untilpatient's hospital discharge, up to 30 daysDescription: change in CRP levels. CRP is an non specific index of inflammation Units: in mg/dL
Measure: inflammation panel: C-reactive Protein (CRP) Time: Daily until patient's hospital discharge, up to 30 daysDescription: change in ESR. ESR is an non specific index of inflammationUnits: mm/h
Measure: inflammation panel: Erythrocyte sedimentation rate (ESR) Time: Daily untilpatient's hospital discharge, up to 30 daysDescription: change in D-Dimer levels. D-Dimer is a fibrin degradation product. Units: 0.5 mcg/ml Fibrinogen Equivalent Units (FEU)
Measure: coagulation panel: D-Dimer Time: Daily until patient's hospital discharge, up to 30 daysDescription: change in fibrinogen levels. Fibrinogen is a protein involved in forming blood clots in the body. Units: mg/dL
Measure: coagulation panel: fibrinogen Time: Daily until patient's hospital discharge, up to 30 daysDescription: change in TT. TT measures the time it takes for a clot to form in the plasma of a blood sample containing anticoagulant, after an excess of thrombin has been added. Units: seconds
Measure: coagulation panel: thrombin clotting time (TT) Time: Daily until patient's hospital discharge, up to 30 daysDescription: change inl aPTT. aPTT measures the overall speed at which blood clots by means of two consecutive series of biochemical reactions. Units: in seconds
Measure: coagulation panel: activated partial thromboplastin time (aPTT) Time: Daily until patient's hospital discharge, up to 30 daysDescription: Change in VAS. VAS is a horizontal line, 100 mm in length, and anchored by word descriptors at each end. The VAS dyspnea score uses "no shortness of breath at all" and "maximum shortness of breath". The patient marks on the line the point that they feel represents the perception of their current state
Measure: Dyspnoea Visual Analog Scale Score (VAS) Time: Daily until patient's hospital discharge, up to 30 daysDescription: change in basal peripheral oxygen saturation percentage (%)
Measure: Oxygen saturation Time: Continuosly, daily until patient's hospital discharge, up to 30 daysDescription: Anteroposterior chest radiography (CXR)
Measure: Evaluation of Lungs conditions Time: Change from baseline, Every three days until patient's hospital discharge, up to 30 daysDescription: Time from hospital admission to discharge from the hospital.
Measure: The total hospital stay Time: up to 30 daysDescription: Change in the amount of hemoglobin per red blood cell. Mean cell hemoglobin is the average mass of hemoglobin per red blood cell in a sample of blood. Units: picograms (pg) per cell
Measure: Mean Corpuscular Hemoglobin (MCH) Time: Daily until patient's hospital discharge, up to 30 daysDescription: change in the size of the red blood cells. Mean cell volume is a measure of the average volume of a red blood corpuscle. Units: femtoliters
Measure: Mean corpuscular volume (MCV) Time: Daily until patient's hospital discharge, up to 30 daysDescription: change in the amount of hemoglobin per unit volume. Mean cell hemoglobin concentration is the average concentration of hemoglobin in a given volume of blood. Unites: g/dl of red blood cells
Measure: mean corpuscular hemoglobin concentration (MCHC) Time: Daily until patient's hospital discharge, up to 30 daysDescription: change in total hemoglobin. Hemoglobin is an indirect way to measure red blood cells. Units: g/ dL
Measure: haemoglobin Hb Time: Daily until patient's hospital discharge, up to 30 daysDescription: Change in the number of red blood cells. Red blood cell count measure anemia. Units: million cells per microliter (cells/mcL)
Measure: Red blood cells count Time: Daily until patient's hospital discharge, up to 30 daysDescription: Change in ketonemia measured as concentration of blood BHB Units: mmol/L
Measure: beta - hydroxybutyrate (BHB) Time: Daily until patient's hospital discharge, up to 30 daysDescription: Change in ALT. ALT is a liver function test. Units: mU/ml
Measure: Alanine transaminase (ALT) Time: Daily until patient's hospital discharge, up to 30 daysDescription: Change in AST. AST ALT is a liver function test. Units : mU/ml
Measure: Aspartate transaminase (AST) Time: Daily until patient's hospital discharge, up to 30 daysDescription: Change in LDH. LDH is a marker of tissues damage. Units: Unites/L
Measure: lactate dehydrogenase (LDH) Time: Daily until patient's hospital discharge, up to 30 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports